Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Alison Barth discovers how different neuron types contribute to cortical function
Barth uses learning tasks in mice as a tool to drive synaptic plasticity in the sensory cortex, hoping to unlock more general principles of how the cortex works.
Alison Barth discovers how different neuron types contribute to cortical function
Barth uses learning tasks in mice as a tool to drive synaptic plasticity in the sensory cortex, hoping to unlock more general principles of how the cortex works.
Virus-like particles deliver gene-editing tools into Duchenne mouse model
The approach uses a protein found in fruit flies to ferry the gene editor Cas9 into muscle cells.
Virus-like particles deliver gene-editing tools into Duchenne mouse model
The approach uses a protein found in fruit flies to ferry the gene editor Cas9 into muscle cells.
Textbook model of hippocampus’s role in memory may need updating
The CA3 region, long thought to have just one circuit, has two, sporting different wiring and functions, a new preprint suggests.
Textbook model of hippocampus’s role in memory may need updating
The CA3 region, long thought to have just one circuit, has two, sporting different wiring and functions, a new preprint suggests.